PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 98042078 |
Filing Date: 06/14/2023 |
Input Field |
Entered |
SERIAL NUMBER | 98042078 |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\980\420\98042078\xml1 \ APP0002.JPG |
SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
LITERAL ELEMENT | Teva api |
COLOR MARK | YES |
COLOR(S) CLAIMED (If applicable) |
The color(s) colors lime green, green, blue and dark blue wing shape V is/are claimed as a feature of the mark. |
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of Leaf and wing shaped. |
PIXEL COUNT ACCEPTABLE | NO |
PIXEL COUNT | 595 x 134 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | TEVA Pharmaceutical Industries Limited |
*MAILING ADDRESS | 124 Dvora HaNevi'a St., |
*CITY | Tel Aviv |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Israel |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
6944020 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Israel |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 001 |
*IDENTIFICATION | Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the manufacture of pharmaceuticals |
FILING BASIS | SECTION 1(b) |
INTERNATIONAL CLASS | 035 |
*IDENTIFICATION | Business management and business management consulting; public relations; business marketing consulting; promotion services, namely, promoting the goods and services of others through dissemination of advertising materials on the Internet; business research services; providing business information to others in the field of pharmaceuticals. |
FILING BASIS | SECTION 1(b) |
ATTORNEY INFORMATION | |
NAME | Laurence Rickles |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | TEVA PHARMACEUTICALS USA, INC. |
INTERNAL ADDRESS | Building A |
STREET | 400 Interpace Parkway |
CITY | Parsippany |
STATE | New Jersey |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 07054 |
EMAIL ADDRESS | Laurence.Rickles@tevapharm.com |
CORRESPONDENCE INFORMATION | |
NAME | Laurence Rickles |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | Laurence.Rickles@tevapharm.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | maureen.manson@tevapharm.com; trademarks.trademarks@tevapharm.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 2 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 700 |
*TOTAL FEES PAID | 700 |
SIGNATURE INFORMATION | |
SIGNATURE | /laurencerickles/ |
SIGNATORY'S NAME | Laurence Rickles |
SIGNATORY'S POSITION | Attorney of Record, NY Bar |
DATE SIGNED | 06/14/2023 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 98042078 |
Filing Date: 06/14/2023 |
The applicant's current Correspondence Information: |
Laurence Rickles |
PRIMARY EMAIL FOR CORRESPONDENCE: Laurence.Rickles@tevapharm.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): maureen.manson@tevapharm.com; trademarks.trademarks@tevapharm.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|